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Abstract Placentas of mice lacking p57Kip2 expression have
trophoblastic hyperplasia. To elucidate the mechanism underly-
ing this phenomenon, we studied expression of two angiogenic
factors, vascular endothelial growth factor (VEGF) and placen-
ta growth factor (PlGF). Immunohistochemical analysis with
anti-VEGF antibodies indicated that VEGF expression was
stronger and more clearly detectable in placentas of p57Kip2
null embryos compared to wild-type placentas. PlGF showed
no signi¢cant di¡erences between placentas of p57Kip2 null and
wild-type embryos. In quantitative analysis, placentas of p57Kip2
null embryos showed higher VEGF messenger (m)RNA and
protein levels than did wild-type placentas. PlGF mRNA and
protein levels were not signi¢cantly di¡erent. These ¢ndings
suggest that VEGF is involved in the hyperplasia that occurs
in placentas of p57Kip2 null embryos.
. 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Proper development of the placenta is dependent on the
formation of trophoblasts. In humans, placental abnormalities
with trophoblastic dysplasia are observed in several preg-
nancy-related diseases including hydatidiform mole, chorio-
carcinoma, pregnancy-induced diabetes and preeclampsia.
However, there are few animal models of placentomegaly
and trophoblast proliferation.
In mammals, imprinted genes are expressed from one of the
parental chromosomes and are crucial for placentation [1].
Recent studies have revealed that imprinted genes are closely
related to trophoblastic disease [2]. For example, genomic
imprinting is important in the generation of the hydatidiform
mole, which is characterized by absence of the maternal ge-
nome and grossly swollen villi [3].
The cell cycle of trophoblastic cells is regulated by cyclins as
well as other factors. The cyclin-dependent kinase (CDK) in-
hibitor p57Kip2 has the ability to bind to a variety of cyclin^
CDK complexes and to inhibit their kinase activities in vitro.
The p57Kip2 gene is a paternally imprinted gene that is tran-
scriptionally repressed and methylated, and is therefore ex-
pressed predominantly from the maternal allele. The p57Kip2
gene is located within a cluster of imprinted genes in both
humans (chromosome 11p15.5) and mice (distal chromosome
7). In humans, loss of the maternally derived 11p15.5 region is
implicated in sporadic tumors and in Beckwith^Wiedemann
syndrome (BWS), which is characterized by congenital mal-
formations and organomegaly and is associated with an in-
creased risk for the development of childhood neoplasms.
Abnormal expression of imprinted genes is implicated in the
pathogenesis of certain pediatric tumors. p57Kip2 mutations
have been found only rarely in association with BWS, but a
decrease in p57Kip2 expression levels has been detected in sev-
eral kinds of tumors [4,5].
Mice de¢cient in the p57Kip2 gene show defective endochon-
dral bone formation. Most of these mice die shortly after
birth, as a result of severe cleft palate. Zhang et al. reported
that p57Kip2 knockouts display organomegaly and abdominal
wall defects, two of the hallmarks of BWS, and they found no
p57Kip2 de¢cient mice that survived beyond the neonatal peri-
od [6]. To the contrary, Yan et al. and Takahashi et al. re-
ported that p57Kip2 de¢cient mice displayed no features of
BWS, and they observed a 10% survival rate [7,8]. The reports
of surviving mutant mice did not indicate it p57Kip2 de¢cient
mice had tumorous tissues.
Changes in p57Kip2 expression have recently been associated
with abnormal trophoblastic proliferation [9]. That is, p57Kip2
expression has been shown to be reduced markedly in women
with malignant trophoblastic neoplasms that cause spontane-
ous abortion and preterm delivery. Furthermore, placentas of
p57Kip2 null embryos have hyperplasia involving both labyrin-
thine trophoblasts and spongiotrophoblasts [10]. Placentation
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is thought to be controlled by cytokines, growth factors, and
hypothalamic hormones that are secreted by endocrine organs
including the placenta. Vascular endothelial growth factor
(VEGF) and placenta growth factor (PlGF) are the best char-
acterized angiogenic factors with respect to placentation
[11,12].
The purpose of the present study was to clarify the relation-
ship between VEGF, PlGF and trophoblast proliferation in
Fig. 1. Histologic ¢ndings of placentas from p57Kip2 null embryos and wild-type embryos. Detection of VEGF by immunoperoxidase staining
in placentas of p57Kip2 null embryo (17.5 d.p.c.) (A) and wild-type embryo (17.5 d.p.c.) (B). In the labyrinthine trophoblast layer, VEGF-posi-
tive cells are more abundant in placentas of p57Kip2 null embryo in comparison to wild-type placentas, as indicated by the arrow.
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placentas of p57Kip2 null embryos. Both VEGF and PlGF
stimulate migration and proliferation of endothelial cells. In
embryos, alternative splicing yields at least three di¡erent
VEGF isoforms, VEGF120, VEGF164, and VEGF188 [13].
VEGF has been implicated in the process of neovasculari-
zation during organogenesis and regeneration, as well as in
the process of blood vessel proliferation during tumor for-
mation [14]. VEGF increase also causes increased vascular
permeability [15]. Many investigators have suggested that
VEGF plays an important role in villous angiogenesis and
trophoblast di¡erentiation [16^18]. However, it is unknown
whether placental levels of VEGF are increased in patients
with pregnancy-induced disease. In the present study we in-
vestigated the expression of VEGF and PlGF protein and
messenger (m)RNA levels in placentas of p57Kip2 null em-
bryos.
Fig. 2. Immunoblot analysis of VEGF and PlGF proteins in placentas of p57Kip2 null embryos and wild-type embryos. A: VEGF164 ; lanes 1^4
show placentas of p57Kip2 null embryos. Lanes 5^8 show wild-type placentas. Alpha-tubulin expression from the same samples served as an in-
ternal control to verify equal protein loading. B: PlGF; lanes 1 and 2 show placentas of p57Kip2 null embryos. Lanes 3 and 4 show wild-type
placentas. C: Densitometric analysis of VEGF164 protein. Relative expression levels were obtained, in each sample, by normalization of abso-
lute VEGF164 of the speci¢c target to that of alpha-tubulin signal. Error bars indicate standard deviation. **P6 0.01 compared with wild-type
embryos.
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2. Materials and methods
2.1. Mice
The mice used in this study carry a targeted mutation in the p57Kip2
locus and were provided by Nippon Roche Research Center. The
materials derived from p57Kip2 null embryos were genotyped by poly-
merase chain reaction (PCR) [8].
2.2. Immunohistological analysis
All placentas were placed in 4% paraformaldehyde in phosphate-
bu¡ered saline (PBS) for 24 h and then in PBS with 10% sucrose until
they were processed and embedded in para⁄n. The sections were cut
(4 Wm thick). After being dried overnight at room temperature, sec-
tions were depara⁄nized with xylene. Sections were then rehydrated
through graded ethanols.
Specimens were treated with 0.3% H2O2 for 10 min to block en-
dogenous peroxidase activity, and preimmune goat serum was used to
block non-speci¢c binding sites. Sections were then incubated over-
night at 4‡C with anti-VEGF antibody (Neo markers, Fremont, CA,
USA). After three washes with PBS, sections were incubated with
biotinylated secondary antibody followed after washing by strepta-
vidin biotin peroxidase. Sections were counterstained with hematox-
ylin.
2.3. Immunoblot analysis
Levels of VEGF and PlGF proteins were assessed by Western blot-
ting. Total lysates of placentas were prepared with Tween 20 lysis
bu¡er as described previously [8]. Protein concentrations were deter-
mined with the Bradford method (protein assay; Bio-Rad, Hercules,
CA, USA). Total lysates (50 Wg/lane) were separated by electropho-
resis on 15% polyacrylamide gels and transferred to Immobilon trans-
fer membranes (Millipore, Bedford, MA, USA). We used polyclonal
rabbit anti-mouse VEGF and goat anti-mouse PlGF antibodies (San-
ta Cruz Biotechnology, Santa Cruz, CA, USA) as primary antibodies.
The secondary antibodies were peroxidase-conjugated sheep anti-rab-
bit antibody (for VEGF, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and anti-goat antibody (for PlGF, Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The signal was visualized with enhanced
chemiluminescence (ECL) detection system according to the manufac-
turer’s instructions. Relative intensities of VEGF protein levels were
analyzed densitometrically (ATTO Corporation, Tokyo, Japan) and
compared with Image Saver software (ATTO Corporation, Tokyo,
Japan). Protein levels were normalized to those of alpha-tubulin.
All experiments were repeated in triplicate, and mean intensities R
standard deviations were calculated.
2.4. Quantitative real-time reverse transcription (RT)-PCR
RT reaction of 2 Wg total RNA was carried out using M-MLV
reverse transcriptase (Gibco BRL, Gaithersburg, MD, USA). Samples
were incubated at 42‡C for 60 min, at 95‡C for 2 min, and ¢nally
cooled on ice.
Real-time PCR from VEGF and PlGF cDNA templates was per-
formed with the use of SYBR Green PCR bu¡er (Perkin Elmer Ap-
plied Biosystems, Foster City, CA, USA) containing 0.4 WM each
primer, 0.6 U AmpliTaq Gold DNA polymerase (Roche Molecular
Biochemicals, Indianapolis, IN, USA), and dNTP blend. Each reac-
tion contained 100 ng of cDNA as templates. The reaction were run
in the well after optimizing the conditions for multiplexing, as de-
scribed previously [19]. The reactions were performed in a ¢nal vol-
umes of 50 Wl. The each primers were follows; VEGF (a) sense and
VEGF (a) anti-sense (accession number NM_009505 VEGF (a) sense
5P-GCA CAC AGG ACG GCT TGA AGA T-3P position 168 and
VEGF (a) anti-sense 5P-CCC ACG ACA GAA GAG CAG A-3P
position 297, product length 151 bp) and PlGF sense and PlGF
anti-sense (accession number NM_008827, forward primer 5P-CCC
ACA CCC AGC TCA CGT ATT TA-3P and reverse primer
5P-TCC CCT CTA CAT GCC TTC AAT GC-3P). The thermal cy-
cling conditions of the ABI PRISM 5700 Sequence Detection instru-
ment (Applied Biosystems, Foster City, CA, USA) were used with 40
cycles of 15 s at 95‡C alternating with 1 min 60‡C. Samples were
analyzed in triplicate. As control reaction, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was included in each run and the
speci¢city of the ampli¢cation reaction was checked by melting curve
analysis. PCR data were obtained by considering the log-linear por-
tion of the £uorescence curve. Analysis of these data was done as
described previously [20].
2.5. RT-PCR
RT reactions were described in Section 2.4. The nucleotide sequen-
ces of the primers were VEGF (forward primer 5P-ACA TCT TCA
AGC CGT CCT GTG TGC-3P and reverse primer 5P-AAA TGG
CGA ATC CAG TCC CAC GAG-3P) [21] and PlGF (primers were
those described in Section 2.4). Primers spanning the VEGF gene
ampli¢ed the three reported mRNA variants, VEGF120, VEGF164,
VEGF188, as the expected 431, 563, and 635 bp products, respectively.
Primers spanning the PlGF gene ampli¢ed 364 bp products. Reactions
were carried out in a DNA thermal cycler 480 (Takara, Tokyo, Ja-
pan). Taq DNA polymerase was used for hot-start (94‡C for 10 min)
prior to the ampli¢cation cycles, and a terminal elongation step (72‡C
for 10 min) following the ampli¢cation cycles.
Thirty cycles were used for the PCR ampli¢cation. The cycling
temperatures and timings for VEGF gene were: 94‡C for 1 min,
62‡C for 1.5 min, and 72‡C for 1 min. The cycling temperatures
and timings for PlGF gene were: 94‡C for 1 min, 61‡C for 1.5 min,
and 72‡C for 1 min.
PCR products were resolved on 2.0% agarose/TAE gels containing
Fig. 3. Quantitative analysis of total VEGF and PlGF mRNAs in placentas of p57Kip2 null embryos and wild-type embryos. Total VEGF and
PlGF mRNA levels were determined by real-time RT-PCR. GAPDH was used to normalize these data. A: Relative increase of total VEGF
mRNA; *P6 0.05 compared with wild-type embryos. B: Relative increase of PlGF mRNA; error bars indicate standard deviation. The
amounts of standard samples were plotted versus threshold cycle in duplicate (data not shown).
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3 Wg/ml ethidium bromide and visualized under UV light. VEGF and
PlGF levels were normalized to those of housekeeping gene GAPDH.
2.6. Statistical analysis
All data were analyzed using Student’s t-test. Di¡erences were con-
sidered to be statistically signi¢cant if P6 0.05.
3. Results
3.1. Increase of VEGF164 protein levels in placentas of p57Kip2
null embryos
Immunohistochemical analysis with anti-VEGF speci¢c
antibody showed strong positive staining for VEGF in the
labyrinthine layers of placentas of p57Kip2 null embryos, as
compared with those of wild-type embryos. (Fig. 1A,B) It had
been reported that placentas of p57Kip2 null embryos dis-
played trophoblastic hyperplasia.
Immunoblot analysis was used access the VEGF protein
levels. VEGF isoforms were identi¢ed by apparent molecular
weight. VEGF164 protein levels in placentas of p57Kip2 null
embryos were higher than those of wild-type embryos (Fig.
2A). VEGF120, VEGF164 and VEGF188 protein levels were
compared in placentas of p57Kip2 null and wild-type embryos
by using densitometric analysis. VEGF164 protein levels were
approximately nine-fold higher in placentas of p57Kip2 null
embryos than in those of wild-type embryos (Fig. 2C). How-
ever VEGF120 and VEGF188 were detected, these two protein
levels did not di¡er signi¢cantly (data not shown). Levels of
PlGF protein did not di¡er signi¢cantly between placentas of
p57Kip2 null embryos and wild-type embryos (Fig. 2B).
3.2. Increase of total VEGF mRNA levels in placentas of
p57Kip2 null embryos
We measured total VEGF mRNA levels to investigate
whether the increase of VEGF protein levels was caused by
an increase of VEGF mRNA levels.
Real-time RT-PCR quanti¢cation of total VEGF and PlGF
mRNA levels in placentas of p57Kip2 null embryos and wild-
type embryos is shown in Fig. 3. These values were normal-
ized to GAPDH. Total VEGF mRNA levels in placentas of
p57Kip2 null embryos were approximately 2.5-fold higher than
in placentas of wild-type embryos (Fig. 3A). PlGF mRNA
levels were not signi¢cantly di¡erent between the groups
(Fig. 3B). Other PCR primer sets were used to distinguish
each VEGF isoform. RT-PCR showed that transcripts for
VEGF120, VEGF164, and VEGF188 showed similar relative
levels in placentas of both p57Kip2 null embryos and wild-
type embryos (Fig. 4A). Note that ampli¢cation e⁄ciencies
may vary for the di¡erent products, so that relative amounts
of the various isoforms within one sample cannot be deter-
mined. Expression of PlGF again did not di¡er signi¢cantly
between placenta of p57Kip2 null embryos and wild-type pla-
centas (Fig. 4B).
4. Discussion
The purpose of this research was to clarify the relationship
between (i) VEGF and PlGF expression levels and (ii) tropho-
blastic proliferation in placentas of p57Kip2 null embryos. We
previously reported that p57Kip2 contributes to proper devel-
Fig. 4. Expression of VEGF isoforms (A) and PlGF mRNA (B) mRNA in placentas of p57Kip2 null embryos and wild-type embryos. Reverse-
transcribed RNA was ampli¢ed by PCR with primers derived from exons shared by VEGF120, VEGF164 and VEGF188 mRNA species, which
thus amplify all VEGF and PlGF isoforms. Products of 431, 563, and 635 bp correspond to the isoforms indicated at the right. The PlGF
product is 364 bp. The corresponding ampli¢cation of GAPDH mRNA from the same RT reaction is depicted; GAPDH product comprises
450 bp. Lanes 1, 2, 3, 6 and 7 show placentas of p57Kip2 null embryos. Lanes 4, 5, 8 and 9 show placentas of wild-type embryos. M= size
marker.
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opment of labyrinthine trophoblasts and spongiotrophoblasts
through pathways not associated with regulation of CDK
activity, as assessed by analysis of p57Kip2 null mice [10].
We found that pregnant p57Kip2 heterozygous female mice
that gestated embryos lacking p57Kip2 expression have hy-
pertension, proteinuria, thrombocytopenia, decreased anti-
thrombin III activity, and increased endothelin levels during
late pregnancy [22]. In this study, we found using immunohis-
tochemical analysis that VEGF is expressed at high levels in
the labyrinthine layers of p57Kip2 null embryos. Furthermore,
our ¢ndings indicate that levels of total VEGF mRNA and
VEGF164 protein levels are higher in placentas of p57Kip2 null
embryos than in those of wild-type embryos. We found that
placentas of p57Kip2 null embryos express the same comple-
ment of VEGF isoforms by using RT-PCR. This suggests that
p57Kip2 does not markedly a¡ect VEGF splicing, although an
increase in speci¢cally the VEGF164 isoform might have been
expected based on the Western blot analysis. We have at
present no explanation for this discrepancy. VEGF164 plays
an important role in placentation [23]. PlGF mRNA and pro-
tein levels were not signi¢cantly di¡erent between placentas of
p57Kip2 null embryos and wild-type embryos. These results
reveal that there is a close association between VEGF levels
and placentation.
Among VEGF isoforms, VEGF164 protein levels were sig-
ni¢cantly increased in placentas of p57Kip2 null embryos.
VEGF164 shows more potent induction of tumorigenesis
than do the other VEGF isoforms in human [24]. Our data
sheds some light on the proliferation of trophoblasts in pre-
eclampsia, which is induced placental hyperplasia.
The loss of p57Kip2 expression is involved in abnormal an-
drogenic proliferation of trophoblasts [9]. p57Kip2 may also
have marked e¡ects on several stages of placental develop-
ment and preeclampsia. It has been assumed that preeclamp-
sia is due to de¢cient trophoblast invasion of the placental bed
spiral arteries, resulting in poor perfusion of the fetoplacental
unit and placenta, which leads to secretion of vasoactive sub-
stances into the maternal circulation. Because VEGF is ex-
pressed in the placenta and VEGF production can be induced
by hypoxia, changes in levels of VEGF may contribute to the
etiology of preeclampsia.
However, it is unclear whether placental VEGF levels are
associated with serum VEGF levels in preeclampsia [25,26].
Cooper, et al. [27], reported that expression of VEGF mRNA
is reduced signi¢cantly in placentas of women with preeclamp-
sia in comparison to placentas of normal pregnant women. In
contrast, Brockelsby, et al. [28] reported that placentally de-
rived VEGF appears to be responsible for the increased cir-
culating levels of VEGF in preeclampsia.
In general, the birth of a healthy infant at term is dependent
upon normal placental development. Conversely, abnormal
placentation is responsible for a wide range of pregnancy-re-
lated complications, including miscarriage, preeclampsia, in-
trauterine growth retardation, and placental abruption. In the
future, study of placentas of p57Kip2 null embryos may clarify
the mechanisms involved in early and late placental dysfunc-
tion and trophoblast proliferation. From this standpoint, we
think that placentas of p57Kip2 null embryos provide a new
animal model of trophoblastic hyperplasia with VEGF in-
crease and a new means of studying the mechanisms of de-
fective placentation.
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